REGENERON PHARMACEUTICALS, INC. Deferred Income Tax Assets, Net
REGENERON PHARMACEUTICALS, INC. (REGN) had Deferred Income Tax Assets, Net of $4.38 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2026-07-30
- 2026-06-30: Deferred Income Tax Assets, Net $4.38B.
- 2026-03-31: Deferred Income Tax Assets, Net $4.19B.
- 2025-12-31: Deferred Income Tax Assets, Net $4.08B.
- 2025-09-30: Deferred Income Tax Assets, Net $3.85B.
| Period end | Deferred Income Tax Assets, Net | Deferred Income Tax Assets, Net as first filed |
|---|---|---|
| 2026-06-30 | $4.38B 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $4.19B 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $4.08B 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $3.85B 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $3.57B 10-Q · filed 2025-08-01 | |
| 2025-03-31 | $3.44B 10-Q · filed 2025-04-29 | |
| 2024-12-31 | $3.31B 10-K · filed 2026-02-04 | |
| 2024-09-30 | $3.02B 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $2.88B 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $2.76B 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $2.58B 10-K · filed 2025-02-05 | |
| 2023-09-30 | $2.32B 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $2.14B 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $1.92B 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $1.72B 10-K · filed 2024-02-05 | |
| 2022-09-30 | $1.45B 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $1.35B 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $1.14B 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $876.90M 10-K · filed 2023-02-06 | |
| 2021-09-30 | $723.20M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $746.60M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $765.10M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $858.90M 10-K · filed 2022-02-07 | |
| 2020-09-30 | $804.20M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $774.00M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $771.20M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $824.20M 10-K · filed 2021-02-08 | |
| 2019-09-30 | $808.30M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $821.60M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $829.30M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $828.70M 10-K · filed 2020-02-07 | |
| 2018-09-30 | $562.82M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $545.08M 10-Q · filed 2018-08-02 | |
| 2017-12-31 | $506.30M 10-K · filed 2019-02-07 | $506.29M 10-Q · filed 2018-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |